- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Development of therapeutic candidate: Tie2 and Ang2 dual modulator for the next.generation treatment of wAMD and DR. | ||||||
| Antibody | wet AMD/DR | Ang2.targeting Tie2 receptor | Candidate | Neortesbio Co.,Ltd. | RS-2023-00282960 | ||
| 2 | Development of recombinant protein targeting human complement C5 for dry age.related macular degeneration treatment | ||||||
| Antibody | Macular degeneration | Human Complement C5 | Lead | Immunabs Co., Ltd. | RS-2023-00282906 | ||
| 3 | Phase 1 clinical study of first in class tie2 activator PMC.403 in patients with age.related macular degeneration | ||||||
| Antibody | Macular degeneration | TIE.2 | Phase 1 | Pharm Abcine Inc. | RS-2023-00282791 | ||
| 4 | Retinal regenerative antibody and gene therapy | ||||||
| Antibody | Degenerative Retinal Disease | PROX1 | Hit | CELLIAZ | RS-2023-00258166 | ||